Hepatocellular Carcinoma Recurrence Post Direct-Acting Antiviral and Its Relation to Time of Treating Chronic HCV Infection

doi:10.21608/ejhm.2024.339695

Home Articles List Article Information

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

The Egyptian Journal of Hospital Medicine

Articles in Press

Current Issue

Journal Archive

Volume 99 (2025)

Volume 98 (2025)

Volume 100 (2025)

Volume 97 (2024)

Volume 96 (2024)

Volume 95 (2024)

Volume 94 (2024)

Issue 1

Volume 93 (2023)

Volume 92 (2023)

Volume 91 (2023)

Volume 90 (2023)

Volume 89 (2022)

Volume 88 (2022)

Volume 87 (2022)

Volume 86 (2022)

Volume 85 (2021)

Volume 84 (2021)

Volume 83 (2021)

Volume 82 (2021)

Volume 81 (2020)

Volume 80 (2020)

Volume 79 (2020)

Volume 78 (2020)

Volume 77 (2019)

Volume 76 (2019)

Volume 75 (2019)

Volume 74 (2019)

Volume 73 (2018)

Volume 72 (2018)

Volume 71 (2018)

Volume 70 (2018)

Volume 69 (2017)

Volume 68 (2017)

Volume 67 (2017)

Volume 66 (2017)

Volume 65 (2016)

Volume 64 (2016)

Volume 63 (2016)

Volume 62 (2016)

Volume 61 (2015)

Volume 60 (2015)

Volume 59 (2015)

Volume 58 (2015)

Volume 57 (2014)

Volume 56 (2014)

Volume 55 (2014)

Volume 54 (2014)

Volume 53 (2013)

Volume 52 (2013)

Volume 51 (2013)

Volume 50 (2013)

Volume 49 (2012)

Volume 48 (2012)

Volume 47 (2012)

Volume 46 (2012)

Volume 45 (2011)

Volume 44 (2011)

Volume 43 (2011)

Volume 42 (2011)

Volume 41 (2010)

Volume 40 (2010)

Volume 39 (2010)

Volume 38 (2010)

Volume 37 (2009)

Volume 36 (2009)

Volume 35 (2009)

Volume 34 (2009)

Volume 33 (2008)

Volume 32 (2008)

Volume 31 (2008)

Volume 30 (2008)

Volume 29 (2007)

Volume 28 (2007)

Volume 27 (2007)

Volume 26 (2007)

Volume 25 (2006)

Volume 24 (2006)

Volume 23 (2006)

Volume 22 (2006)

Volume 21 (2005)

Volume 20 (2005)

Volume 19 (2005)

Volume 18 (2005)

Volume 17 (2004)

Volume 16 (2004)

Volume 15 (2004)

Volume 14 (2004)

Volume 13 (2003)

Volume 12 (2003)

Volume 11 (2003)

Volume 10 (2003)

Volume 9 (2002)

Volume 8 (2002)

Volume 7 (2002)

Volume 6 (2002)

Volume 5 (2001)

Volume 4 (2001)

Volume 3 (2001)

Volume 2 (2001)

Volume 1 (2000)

	Hepatocellular Carcinoma Recurrence Post Direct-Acting Antiviral and Its Relation to Time of Treating Chronic HCV Infection
Article 74, Volume 94, Issue 1, January 2024, Page 500-505 PDF (345.42 K)
DOI: 10.21608/ejhm.2024.339695
View on SCiNiTO
Abstract
Background: There is a documented relationship between Hepatocellular Carcinoma (HCC) recurrence and Direct‐Acting Antiviral (DAAs). Objective: This study's overarching goal was to determine whether there is a correlation between the length of time between HCV treatments and the frequency of recurrence of HCC following successful ablation of HCC. Patients and Methods: This retrospective study included 400 cases with chronic HCV infection and HCC who had a complete response to treatment. The patients also had to have attended the clinic for HCC recurrence during this time. A total of 200 cases with recurrent HCC were randomly assigned to one of four categories and then exposed to DAA (case group). Fifty patients in each of Groups 1, 2, and 3 began treatment 3, 6, 9, and 12 months following their curative HCC therapy, while 200 patients with recurrent HCC who were not exposed to DAAs served as the control group. Results: The case group's recurrence rate increased significantly throughout the first six months, then decreased during the second half of the study. Conclusion: It appears that the recurrence of HCC in individuals exposed to DAAs is more rapid and aggressive than in those who are not exposed to DAAs. We advise waiting at least one year after an ablative treatment's complete response before beginning DAA treatment.


Statistics Article View: 128 PDF Download: 225